
Ardelyx, Inc. (NASDAQ:ARDX – Free Report) – Equities research analysts at HC Wainwright upped their FY2026 earnings per share estimates for Ardelyx in a report issued on Wednesday, November 4th. HC Wainwright analyst M. Caufield now anticipates that the biopharmaceutical company will post earnings of ($0.18) per share for the year, up from their prior estimate of ($0.26). HC Wainwright has a “Buy” rating and a $13.00 price objective on the stock. The consensus estimate for Ardelyx’s current full-year earnings is ($0.19) per share. HC Wainwright also issued estimates for Ardelyx’s Q4 2026 earnings at $0.04 EPS, FY2027 earnings at $0.06 EPS, FY2029 earnings at $1.18 EPS and FY2030 earnings at $1.58 EPS.
Ardelyx (NASDAQ:ARDX – Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.02). The firm had revenue of $120.88 million during the quarter, compared to analyst estimates of $121.03 million. Ardelyx had a negative net margin of 11.85% and a negative return on equity of 35.30%. Ardelyx’s revenue was up 34.3% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.08) earnings per share.
Check Out Our Latest Report on Ardelyx
Ardelyx Stock Performance
Shares of Ardelyx stock opened at $2.88 on Friday. The firm’s fifty day simple moving average is $3.35 and its 200-day simple moving average is $5.23. The stock has a market capitalization of $723.95 million, a price-to-earnings ratio of -13.09 and a beta of 0.79. Ardelyx has a 12 month low of $2.84 and a 12 month high of $8.40. The company has a debt-to-equity ratio of 1.54, a current ratio of 3.45 and a quick ratio of 3.15.
Institutional Trading of Ardelyx
A number of institutional investors have recently added to or reduced their stakes in ARDX. Sterling Capital Management LLC increased its holdings in Ardelyx by 842.7% in the third quarter. Sterling Capital Management LLC now owns 8,088 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 7,230 shares in the last quarter. Northwestern Mutual Wealth Management Co. purchased a new stake in shares of Ardelyx during the 2nd quarter worth approximately $35,000. Kestra Advisory Services LLC purchased a new stake in shares of Ardelyx during the 3rd quarter worth approximately $39,000. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Ardelyx in the 3rd quarter worth approximately $44,000. Finally, Vontobel Holding Ltd. acquired a new stake in shares of Ardelyx in the 3rd quarter worth approximately $46,000. Hedge funds and other institutional investors own 58.92% of the company’s stock.
Insiders Place Their Bets
In other Ardelyx news, insider James Brady sold 15,136 shares of the business’s stock in a transaction on Friday, August 21st. The shares were sold at an average price of $3.86, for a total transaction of $58,424.96. Following the sale, the insider directly owned 245,930 shares in the company, valued at approximately $949,289.80. The trade was a 5.80% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Laura A. Williams sold 10,739 shares of the business’s stock in a transaction on Friday, August 21st. The stock was sold at an average price of $3.86, for a total transaction of $41,452.54. Following the sale, the insider owned 367,456 shares in the company, valued at $1,418,380.16. The trade was a 2.84% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 126,059 shares of company stock worth $486,588. Corporate insiders own 5.30% of the company’s stock.
More Ardelyx News
Here are the key news stories impacting Ardelyx this week:
- Positive Sentiment: TD Cowen initiated coverage with a “Strong Buy” rating and reaffirmed its “Buy” view. HC Wainwright also raised its Q4 2026 and FY2026 earnings estimates while maintaining a $13 price target. TD Cowen coverage
- Neutral Sentiment: Ardelyx reported break-even quarterly EPS, beating the consensus estimate of a $0.02 loss, while revenue of $127.66 million narrowly missed forecasts. Revenue rose 21% year over year. Quarterly results
- Negative Sentiment: HC Wainwright cut its EPS estimates for FY2027 through FY2030, including a reduction for FY2029 from $1.56 to $1.18. The cuts temper the bullish implications of its higher near-term forecasts, despite its continued “Buy” rating and $13 target. Analyst estimates
- Negative Sentiment: Law firms are publicizing a filed securities class action covering investors who bought shares from January 13, 2025, through August 6, 2026; the lead-plaintiff deadline is November 16. The complaint alleges Ardelyx misrepresented payer access and reimbursement barriers affecting IBSRELA and XPHOZAH, and its sales outlook. The allegations are unproven, but the litigation adds uncertainty. Class action notice and allegations
About Ardelyx
Ardelyx, Inc is a biopharmaceutical company focused on developing and commercializing therapies for gastrointestinal and cardiorenal diseases. The company’s platform is centered on regulating ion transport in the gut, with the goal of addressing conditions that are inadequately served by existing treatments.
Ardelyx’s marketed products include IBSRELA (tenapanor), an oral treatment for adults with irritable bowel syndrome with constipation, and XPHOZAH (tenapanor), a therapy designed to reduce serum phosphorus in adults with chronic kidney disease on dialysis who have an inadequate response to, or are intolerant of, phosphate binders.
Further Reading
- Five stocks we like better than Ardelyx
- Dutch Bros Gave Wall Street What It Wanted, So Why Did the Stock Crater?
- Astera Labs Just Crushed Earnings—So Why Are Analysts Cutting Price Targets?
- Sandisk Shares Are Oversold: Bargain or Value Trap?
- IonQ’s Record Revenue Includes a Big SkyWater Boost: Does That Change the Story?
Receive News & Ratings for Ardelyx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ardelyx and related companies with MarketBeat.com's FREE daily email newsletter.
